Clarithromycin resistance in Helicobacter pylori: Prevalence in untreated dyspeptic patients and stability in vitro

Journal of Antimicrobial Chemotherapy

Volumn 37, Issue 3, 1996, Pages 473-481

  Xia, Hua Xiang ^a,c   Buckley, Martin ^b   Keane, Conor T ^a   O'Morain, Colm A ^b  

^a ST JAMES S HOSPITAL   (Ireland)

^b ADELAIDE AND MEATH HOSPITAL   (Ireland)

^c NEPEAN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; ANTIBIOTIC AGENT; CLARITHROMYCIN; ERYTHROMYCIN; METRONIDAZOLE;

ADOLESCENT; ADULT; AGE; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; CROSS RESISTANCE; DIFFUSION; DILUTION; DYSPEPSIA; FEMALE; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEPTIC ULCER; SEX DIFFERENCE;

ADULT; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG RESISTANCE, MICROBIAL; DYSPEPSIA; ERYTHROMYCIN; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PREVALENCE;

EID: 0029921593     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/37.3.473     Document Type: Article

References (31)

1. Andrews, J. & Wise, R. (1993). Disk susceptibility testing for clarithromycin. European Journal of Clinical Microbiology and Infectious Diseases 12, 972-94.
2. Bazzoli, F., Zagari, R. M., Fossi, S., Pozzato, P., Alampi, G., Simoni, P. et al., (1994). Short-term low-dose triple therapy for the eradication of Helicobacter pylori. European Journal of Gastroenterology and Hepatology 6, 773-7.
3. Bell, G. D., Powell, K., Burridge, S. M., Pallecaros, A., Jones, P. H., Gant P. W. el al. (1992). Experience with "triple" anti-Helicobacier pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance. Alimentary Pharmacology and Therapeutics 6, 427-35.
4. Coghlan, J. G., Gilligan, D., Humphries, H., McKenna, D., Dooley, C., Sweeney, E. et al. (1987). Campylobacter pylori and recurrence of duodenal ulcer - a 12-month follow-up study. Lancet ii, 1109-11.
5. Glupczynski, Y. & Burette, A. (1990). Drug therapy for Helicobacter pylori infection: problems and pitfalls. American Journal of Gastronenterology 85, 1545-51.
6. Goldman, R. C., Zakula, D., Flamm, R., Beyer, J. & Capobianco, J. (1993). Tight binding of clarithromycin, its 14-(R)-hydroxy metabolite, and erythromycin to Helicobacter pylori ribosomes. Antimicrobial Agents and Chemotherapy 38, 1496-1500.
7. Graham, D. Y., Lew, G. M., Malaty, H. M., Evans, D. G., Evans, D. J., Klein, P. D. et al. (1992). Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 102, 493-6.
8. Graham, D. Y., Operkun, A. R. & Klein, P. D. (1993). Clarithromycin for the eradication of Helicobacter pylori. Journal of Clinical Gastroenterology 16, 292-4.
9. Hardy, D. J., Hanson, C. W., Hensey, D. M., Beyer, J. M. & Fernandes, P. (1988a). Susceptibility of Campylobacter pylori to macrolides and fluoroquinolones. Journal of Antimicrobial Chemotherapy 22, 631-6.
10. Hardy, D. J., Hensey, D. M., Beyer, J. M., Vojtko, C., MaDonald, E. J. & Fernandas, P. B. (1988b). Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrobial Agents and Chemotherapy 32, 1710-9.
11. Hardy, D. J., Swanson, R. N., Rode, R. A., Marsh, K., Shipkowitz, N. L. & Clement, J. J. (1990). Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans. Antimicrobial Agents and Chemotherapy 34, 1407-13.
12. Jonas, C., de Koster, E., van Gossum, M., Depierreux, M., Glupczynski, Y. & Deltenre, M. (1993). An evaluation of 10 days clarithromycin-omeprazole-bismuth. Acta Gastro-Enterologica Belgica 56, Suppl. Abstract, p. 137.
13. Labenz, J., Stolte, M., Rühl, G. H., Becker, T., Tillenburg, B., Sollböhmer, M. et al. (1995). One-week low-dose triple therapy for the eradication of Helicobacter pylori infection. European Journal of Gastroenterology and Hepatology 7, 9-11.
14. Lamouliatte, H., Cayla, R., Mégraud, F., Zerbib, F., Stablo, M., Bouchard, S. et al. (1993). Randomised controlled trial with omeprazole and antibiotics in a combined treatment for Helicobacter pylori eradication. Preliminary results. Acta Gastro-Enterologica Belgica 56, Suppl. Abstract, p. 139.
15. Leading Article. (1990). Gastroenterologists in Sydney - histology and Helicobacter. Lancet 336, 779-80.
16. Logan, R. P. H., Gummett, P. A., Schaufelberger, H. D., Greaves, R. R. F. H., Mendelson, G. M., Walker, M. M. et al. (1994). Eradication of Helicobacter pylori with clarithromycin and omeprazole. Gut 35, 323-6.
17. Malanoski, G. J., Eliopoulos, G. M., Ferraro, M. J. & Moelleringn R. C. (1993). Effect of pH variation on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temafloxacin. European Journal of Clinical Microbiology & Infectious Diseases 12, 131-3.
18. Mégraud, F. (1994). H. pylori resistance to antibiotics. In Belicobacter pylori: Basic Mechanisms to Clinical Cure. Proceedings of the International Symposium, Florida, USA, 1993. (Hunt, R. H. & Tytgat, G. N. J., Eds), pp. 570-83. Kluwer Academic Publishers, Dordrecht.
19. National Committee for Clinical Laboratory Standards. (1990). Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria. Approved Standard M11-A2. NCCLS, Villanova, PA.
20. O'Riordan, T., Mathai, E., Tobin, E., McKenna, D., Keane, C., Sweeney, E. et al. (1990). Adjuvant antibiotic therapy in duodenal ulcer treated with colloidal bismuth subcitrate. Gut 31, 999-1002.
21. 2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin. Antimicrobial Agents and Chemotherapy 38, 211-6.
22. Thijs, J. C., van Zwet, A. A., Moolenaar, W., Oom, J. A. J., de Kortes, H. & Runhaar, E. A. (1994). Clarithromycin. an alternative to metronidazole in the triple therapy of Helicobacter pylori infection. Alimentary Pharmacology and Therapeutics 8, 131-4.
23. Versalovic, J., Kibler, K., Small, S., Graham, D. Y. & Go, M. F. (1995). Mutations in 23S ribosomal RNA confer clarithromycin resistance in Helicobacter pylori. Gut 37, Suppl. 1, A67.
24. Weisblum, B. (1995). Erythromycin resistance by ribosome modification. Antimicrobial Agents and Chemotherapy 39, 577-85.
25. Xia, H. X., Buckley, M., Hyde, D., Keane, C. T. & O'Morain, C. A. (1995). Effects of antibiotic-resistance on clarithromycin-combined triple therapy for Helicobacter pylori. Gut 37, Suppl. 1, A55.
26. Xia, H. X., Daw, M. A., Beattie, S., Keane, C. T. & O'Morain, C. A. (1993a). Prevalence of metronidazole-resistant Helicobacter pylori in dyspeptic patients. Irish Journal of Medical Science 162, 91-4.
27. Xia, H. X., Daw, M. A., Keane, C. T. & O'Morain, C. A. (1991). Helicobacter pylori -emergence of metronidazole-resistant isolates. Journal of Medical Microbiology 35, Abstract ix.
28. Xia, H. X., Daw, M. A., Sant, S., Beattie, S., Keane, C. T. & O'Morain, C. A. (1993b). Clinical efficacy of triple therapy in Helicobacter pylori-associated duodenal ulcer. European Journal of Gastroenterology and Hepatology 5, 141-4.
29. Xia, H. X., Keane, C. T., Beattie, S. & O'Morain, C. A. (1994a). Standardization of disc diffusion test and its clinical significance for susceptibility testing of metronidazole against Helicobacter pylori. Antimicrobial Agents and Chemotherapy 38, 2357-61.
30. Xia, H. X., Keane, C. T. & O'Morain, C. A. (19946). Culture of Helicobacter pylori under aerobic conditions on solid media. European Journal of Clinical Microbiology and Infectious Diseases 13, 406-9.
31. Xia, H. X., Keane, C. T. & O'Morain, C. A. (1994c). Pre-formed urease activity of Helicobacter pylori as determined by a viable cell count technique-clinical implications. Journal of Medical Microbiology 40, 435-9.